John H Greist

Summary

Affiliation: Healthcare Technology Systems
Country: USA

Publications

  1. ncbi Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine
    John Greist
    Healthcare Technology Systems, Madison, Wisconsin 53717, USA
    Clin Ther 26:1446-55. 2004
  2. ncbi WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults
    John H Greist
    Healthcare Technology Systems, Inc, Madison, Wisconsin 53717, USA
    CNS Spectr 8:7-16. 2003
  3. ncbi Telephonic Remote Evaluation of Neuropsychological Deficits (TREND): longitudinal monitoring of elderly community-dwelling volunteers using touch-tone telephones
    James C Mundt
    Healthcare Technology Systems, Inc, Madison, WI 53717, USA
    Alzheimer Dis Assoc Disord 21:218-24. 2007
  4. doi Feasibility and validation of a computer-automated Columbia-Suicide Severity Rating Scale using interactive voice response technology
    James C Mundt
    Healthcare Technology Systems, Inc, 7617 Mineral Point Road, Ste 300, Madison, WI 53717, USA
    J Psychiatr Res 44:1224-8. 2010
  5. ncbi An examination of 26,168 Hamilton Depression Rating Scale scores administered via interactive voice response across 17 randomized clinical trials
    Heidi K Moore
    Healthcare Technology Systems, Inc Madison, WI 53717, USA
    J Clin Psychopharmacol 26:321-4. 2006
  6. ncbi Factors contributing to failed trials of new agents: can technology prevent some problems?
    John H Greist
    Healthcare Technology Systems, Inc, 7617 Mineral Point, Suite 300, Madison, WI 53717, USA
    J Clin Psychiatry 63:8-13. 2002
  7. ncbi A pilot study of an electronic, adolescent version of the quick inventory of depressive symptomatology
    Heidi K Moore
    Healthcare Technology Systems, Inc, Madison, WI 53717, USA
    J Clin Psychiatry 68:1436-40. 2007
  8. ncbi The Work and Social Adjustment Scale: a simple measure of impairment in functioning
    James C Mundt
    Healthcare Technology Systems Inc, 7617 Mineral Point Road, Suite 300, Madison, WI 53717, USA
    Br J Psychiatry 180:461-4. 2002
  9. ncbi Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study
    Kenneth A Kobak
    Dean Foundation for Health, Research and Education, Middleton, Wisconsin, USA
    J Clin Psychopharmacol 22:257-62. 2002
  10. pmc Using daily interactive voice response assessments: to measure onset of symptom improvement with duloxetine
    Heidi K Moore
    Healthcare Technology Systems, Inc, Madison, Wisconsin, USA
    Psychiatry (Edgmont) 4:30-8. 2007

Detail Information

Publications27

  1. ncbi Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine
    John Greist
    Healthcare Technology Systems, Madison, Wisconsin 53717, USA
    Clin Ther 26:1446-55. 2004
    ..This analysis assessed the incidence, severity, onset, and duration of nausea among patients with major depressive disorder (MDD) treated with the new antidepressant duloxetine...
  2. ncbi WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults
    John H Greist
    Healthcare Technology Systems, Inc, Madison, Wisconsin 53717, USA
    CNS Spectr 8:7-16. 2003
    ..Further, pharmacotherapy for a minimum of 1-2 years is recommended before very gradual withdrawal may be considered...
  3. ncbi Telephonic Remote Evaluation of Neuropsychological Deficits (TREND): longitudinal monitoring of elderly community-dwelling volunteers using touch-tone telephones
    James C Mundt
    Healthcare Technology Systems, Inc, Madison, WI 53717, USA
    Alzheimer Dis Assoc Disord 21:218-24. 2007
    ..Such assessments might benefit routine clinical care and large-scale, longitudinal research in the future, but will require additional research over longer periods...
  4. doi Feasibility and validation of a computer-automated Columbia-Suicide Severity Rating Scale using interactive voice response technology
    James C Mundt
    Healthcare Technology Systems, Inc, 7617 Mineral Point Road, Ste 300, Madison, WI 53717, USA
    J Psychiatr Res 44:1224-8. 2010
    ....
  5. ncbi An examination of 26,168 Hamilton Depression Rating Scale scores administered via interactive voice response across 17 randomized clinical trials
    Heidi K Moore
    Healthcare Technology Systems, Inc Madison, WI 53717, USA
    J Clin Psychopharmacol 26:321-4. 2006
    ....
  6. ncbi Factors contributing to failed trials of new agents: can technology prevent some problems?
    John H Greist
    Healthcare Technology Systems, Inc, 7617 Mineral Point, Suite 300, Madison, WI 53717, USA
    J Clin Psychiatry 63:8-13. 2002
    ..This article describes methodological factors that can confound study outcomes and discusses the potential for interactive voice response (IVR) technology to address some of these problems...
  7. ncbi A pilot study of an electronic, adolescent version of the quick inventory of depressive symptomatology
    Heidi K Moore
    Healthcare Technology Systems, Inc, Madison, WI 53717, USA
    J Clin Psychiatry 68:1436-40. 2007
    ..An adolescent version of the QIDS (QIDS-A-IVR) was created using speaker-independent voice recognition technology. An informant version, QIDS-P-IVR, collects ratings from parents or other knowledgeable adults...
  8. ncbi The Work and Social Adjustment Scale: a simple measure of impairment in functioning
    James C Mundt
    Healthcare Technology Systems Inc, 7617 Mineral Point Road, Suite 300, Madison, WI 53717, USA
    Br J Psychiatry 180:461-4. 2002
    ..Patients' perspectives concerning impaired functioning provide important information. AIMS; To evaluate the reliability and validity of the Work and Social Adjustment Scale (WSAS)...
  9. ncbi Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study
    Kenneth A Kobak
    Dean Foundation for Health, Research and Education, Middleton, Wisconsin, USA
    J Clin Psychopharmacol 22:257-62. 2002
    ..Fluoxetine failed to separate from placebo in this trial. It is unknown whether a larger dose for longer duration would have yielded separation from placebo. A higher than usual placebo response rate was found...
  10. pmc Using daily interactive voice response assessments: to measure onset of symptom improvement with duloxetine
    Heidi K Moore
    Healthcare Technology Systems, Inc, Madison, Wisconsin, USA
    Psychiatry (Edgmont) 4:30-8. 2007
    ..This study provides new data about the usefulness of daily IVR assessments in clinical research and supports other studies regarding early symptom improvement with duloxetine...
  11. pmc The Depression Inventory Development Workgroup: A Collaborative, Empirically Driven Initiative to Develop a New Assessment Tool for Major Depressive Disorder
    Anthony L Vaccarino
    Dr Vaccarino is with Indoc Research, Toronto, Ontario, Canada Dr Evans is with Indoc Research, Toronto, Ontario, Canada, and Department of Pathology and Molecular Medicine, Queen s University, Kingston, Ontario, Canada Dr Kalali is with Quintiles Inc, San Diego, California, USA, and Department of Psychiatry, University of California, San Diego, California, USA Drs Kennedy and Placenza are with University Health Network, Toronto, Ontario, Canada Dr Engelhardt is with Cronos Clinical Consulting Services, Lambertville, New Jersey, USA Dr Frey is with Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada, and Mood Disorders Program and Women s Health Concerns Clinic, St Joseph s Healthcare, Hamilton, Ontario, Canada Dr Greist is with Department of Psychiatry, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA Dr Kobak is with Center for Telepsychology, Madison, Wisconsin, USA Dr Lam is with Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada Dr MacQueen is with Mathison Centre for Mental Health Research and Education, Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada Dr Milev is with Department of Psychiatry
    Innov Clin Neurosci 13:20-31. 2016
    ....
  12. pmc Anchoring perceptions of clinical change on accurate recollection of the past: memory enhanced retrospective evaluation of treatment (MERET)
    James C Mundt
    Healthcare Technology Systems, Inc, Madison, Wisconsin, USA
    Psychiatry (Edgmont) 4:39-45. 2007
    ..To evaluate patients' self-reports of treatment efficacy with and without self-prompted memory aids regarding their clinical experiences obtained prior to treatment initiation...
  13. ncbi Validation of an IVRS version of the MADRS
    James C Mundt
    Healthcare Technology Systems, Inc, 7617 Mineral Point Road, Madison, WI 53717, USA
    J Psychiatr Res 40:243-6. 2006
    ..Clinicians rated the severity of subjects' sadness and pessimistic thoughts lower than subjects self-report. The data obtained in this pilot study provide support for the equivalence between the clinician and IVR versions of the MADRS...
  14. ncbi A novel interactive voice response (IVR) system for dementia screening, education, and referral: one-year summary
    James C Mundt
    Healthcare Technology Systems, Inc, Madison, Wisconsin 53717, USA
    Alzheimer Dis Assoc Disord 19:143-7. 2005
    ..Overall, the 1-year results support the need for accessible and anonymous resources for individuals concerned about dementia...
  15. ncbi Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a control
    John H Greist
    Healthcare Technology Systems, and the University of Wisconsin, Madison, 53717, USA
    J Clin Psychiatry 63:138-45. 2002
    ..This study compared the value of computer-guided behavior therapy value with that of clinician-guided behavior therapy and systematic relaxation as a control treatment...
  16. ncbi The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial
    Terence A Ketter
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, Calif, USA
    J Clin Psychiatry 67:400-6. 2006
    ..This study assessed the impact of specific instructions designed to decrease risk of dermatologic reactions, including nonserious rash, during initiation of and early treatment with lamotrigine in patients with bipolar I disorder...
  17. ncbi Obsessive-compulsive symptom dimensions as predictors of compliance with and response to behaviour therapy: results from a controlled trial
    David Mataix-Cols
    Department of Psychiatry, Imperial College School of Medicine, London, UK
    Psychother Psychosom 71:255-62. 2002
    ..This study examined whether previously identified OCD symptom dimensions are associated with treatment compliance and response to behaviour therapy (BT) for OCD...
  18. ncbi A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder
    Eric Hollander
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Clin Psychiatry 64:640-7. 2003
    ....
  19. ncbi WCA recommendations for the long-term treatment of panic disorder
    Mark H Pollack
    Division of Psychiatry, Huddinge University Hospital, Stockholm, Sweden
    CNS Spectr 8:17-30. 2003
    ..Long-term efficacy and ease of use are important considerations in treatment selection, as maintenance treatment is recommended for at least 12-24 months, and in some cases, indefinitely...
  20. ncbi A comparison of initial duloxetine dosing strategies in patients with major depressive disorder
    Virgil G Whitmyer
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Ind, USA
    J Clin Psychiatry 68:1921-30. 2007
    ..To compare the effects of starting doses of duloxetine taken with or without food on tolerability and efficacy in patients with major depressive disorder (MDD)...
  21. ncbi WCA recommendations for the long-term treatment of social phobia
    Michael Van Ameringen
    Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada
    CNS Spectr 8:40-52. 2003
    ..In light of the chronicity and disability associated with social phobia, as well as the high relapse rate after short-term therapy, it is recommended that effective treatment be continued for at least 12 months...
  22. ncbi St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study
    Kenneth A Kobak
    Dean Foundation for Health Research and Education, Middleton, Wisconsin 53562, USA
    Int Clin Psychopharmacol 20:299-304. 2005
    ..9%) and placebo (16.7%) (P=0.905). Only one patient from each group discontinued due to adverse events [sinus infection (St John's wort); confusion (placebo)]. The results fail to support the efficacy of St John's wort for OCD...
  23. ncbi Cost-effectiveness of computer-aided behaviour therapy for obsessive-compulsive disorder
    Paul McCrone
    Psychother Psychosom 76:249-50. 2007
  24. ncbi Assessing the onset of antidepressant-induced sexual dysfunction using interactive voice response technology
    Judith A Dunn
    Pfizer Global Research and Development, New London, Conn, USA
    J Clin Psychiatry 68:525-32. 2007
    ..The current study was designed to evaluate the validity of obtaining CSFQ data using interactive voice response (IVR) technology...
  25. ncbi Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study
    Andrew A Nierenberg
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA
    Curr Med Res Opin 23:401-16. 2007
    ..The purpose of this non-inferiority study was to compare the speed of onset of antidepressant efficacy for duloxetine (a dual serotonin and norepinephrine reuptake inhibitor) and escitalopram (a selective serotonin reuptake inhibitor)...
  26. ncbi Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine
    Madelaine M Wohlreich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Ann Clin Psychiatry 17:259-68. 2005
    ..We examined the efficacy and tolerability associated with a switch from a selective serotonin reuptake inhibitor (SSRI) or venlafaxine to duloxetine...
  27. ncbi Is it easier to find what you are looking for if you think you know what it looks like?
    James C Mundt
    J Clin Psychopharmacol 27:121-5. 2007